APPLICATION OF IMIDAZOLE COMPLEXES IN THE TREATMENT OF FUNGAL INFECTIONS
DOI:
https://doi.org/10.52754/16948610_2026_2_9%20Keywords:
imidazole, imidazole complexes, fungal infections, mycoses, antifungal agentsAbstract
Relevance. Fungal infections represent one of the most relevant problems in modern clinical medicine due to their high prevalence, chronic course, and increasing resistance of pathogens to conventional antifungal drugs. Of particular importance are superficial and systemic mycoses caused by dermatophytes, yeasts, and molds of the genera Candida, Aspergillus, and Trichophyton. Therefore, the search for new effective and safe antifungal agents remains a priority in pharmacology and medicinal chemistry. The aim of this article is to analyze publications on the use of imidazole-based complexes in the treatment of fungal infections, as well as to evaluate their pharmacological activity, mechanism of action, and prospects for clinical application. Comparative analyses of individual imidazole drugs and their therapeutic effects were conducted. In addition, comparative analyses of dermatophytosis incidence by regions for the period 2019–2023 were performed based on epidemiological data from the Ministry of Health of the Kyrgyz Republic. Imidazole compounds, including drugs such as ketoconazole, clotrimazole, miconazole, and other derivatives, exhibit pronounced fungistatic and fungicidal effects by inhibiting the synthesis of ergosterol, a key component of the fungal cell membrane. Disruption of ergosterol biosynthesis leads to altered membrane permeability and subsequent fungal cell death. The article also analyzes data from modern experimental and clinical studies confirming the effectiveness of imidazole complexes in the treatment of dermatomycoses, mucosal candidiasis, and systemic fungal infections. The use of imidazole complexes represents a promising direction in the development of modern antifungal agents, requiring further in-depth research and clinical evaluation.
References
Адаскевич, В. П. (2007). Противогрибковые лекарственные средства в дерматологии. Вестник фармации, (2), 80–91.
Аймолдина, А. А., Батпенова, Г. Р., Алгазина, Т. О., Котлярова, Т. В., Амантаев, Д. М., Киян, В. С. (2023). Распространенность дерматофитий и их влияние на качество жизни пациентов в мире. Наука и здравоохранение, 25(4), 246–257. https://doi.org/10.34689/SH.2023.25.4.030
Новикова, В. В. (2020). Поиск новых антимикотических средств: основные тенденции и проблемы. Человек и его здоровье, (1), 75–81.
Bartalucci, C., Vena, A., Giacobbe, D. R., & Bassetti, M. (2025). Clinical impact of fluconazole-resistant Candida parapsilosis: a narrative review. Future microbiology, 20(13), 903–912. https://doi.org/10.1080/17460913.2025.2544443
Cerqueira, F., Maia, M., Gabriel, C., Medeiros, R., Cravo, S., Ribeiro, A. I., Dantas, D., Dias, A. M., Saraiva, L., Raimundo, L., & Pinto, E. (2021). Mechanism of antifungal activity by 5-aminoimidazole-4-carbohydrazonamide derivatives against Candida albicans and Candida krusei. Antibiotics, 10(2), 183. https://doi.org/10.3390/antibiotics10020
Elias, R., Basu, P., & Fridman, M. (2022). Fluconazole-COX Inhibitor Hybrids: A Dual-Acting Class of Antifungal Azoles. Journal of medicinal chemistry, 65(3), 2361–2373. https://doi.org/10.1021/acs.jmedchem.1c01807
Fisher, M. C., Alastruey-Izquierdo, A., Berman, J., Bicanic, T., Bignell, E. M., Bowyer, P., Bromley, M., Brüggemann, R., Garber, G., Cornely, O. A., Gurr, S. J., Harrison, T. S., Kuijper, E., Rhodes, J., Sheppard, D. C., Warris, A., White, P. L., Xu, J., Zwaan, B., & Verweij, P. E. (2022). Tackling the emerging threat of antifungal resistance to human health. Nature Reviews Microbiology, 20(9), 557–571. https://doi.org/10.1038/s41579-022-00720-1
Kaldybayeva, A. B., Praliyev, K. D., Sergazy, A., Malmakova, A. Y., & Yu, V. K. (2023). Potential of imidazole-containing derivatives for practical application (Review). Химический журнал Казахстана, (2(82)), 58–78. https://doi.org/10.51580/2023-2.2710-1185.14
Lee, Y., Robbins, N., & Cowen, L. E. (2023). Molecular mechanisms governing antifungal drug resistance. npj Antimicrobial Resistance, 1, 5. https://doi.org/10.1038/s44259-023-00007-2
Liu, S., Hou, Y., Chen, X., Gao, Y., Li, H., & Sun, S. (2014). Combination of fluconazole with non-antifungal agents: a promising approach to cope with resistant Candida albicans infections and insight into new antifungal agent discovery. International journal of antimicrobial agents, 43(5), 395–402. https://doi.org/10.1016/j.ijantimicag.2013.12.009
Patel, P., & Zito, P. M. (2025). Antifungal agents. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK538168/
Samtsov, A. V., Khairutdinov, V., & Gorbunov, Y. G. (2025). The effectiveness of antifungal drugs in dermatomycosis: A systematic review with network analysis. Vestnik dermatologii i venerologii, 101(6), 36–45. https://doi.org/10.25208/vdv16935
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999). Current and emerging azole antifungal agents. Clinical Microbiology Reviews, 12(1), 40–79. https://doi.org/10.1128/CMR.12.1.40
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Кенжекан Исакова , Каным Асанбек кызы , Канышай Максимова , Жыпаргул Талипова , Жыпаргуль Абдуллаева , Айнура Кушбакова , Гаухар Кудайбердиева
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
